Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis

This study compares three treatment approaches for moderate-to-severe ulcerative colitis (UC) — a chronic inflammatory disease of the large intestine: infliximab alone, ustekinumab alone, and a combination of both. Researchers want to see which approach is safest and most effective. **You may be eligible if...** - You are aged 18–65 with a confirmed diagnosis of ulcerative colitis for at least 3 months - Your UC is moderately to severely active - You are willing to use effective contraception during the study if you are a woman of childbearing age **You may NOT be eligible if...** - You have had a bowel surgery that removed part or all of the colon - You have active tuberculosis, a severe infection, or certain cancers - You are pregnant or planning to become pregnant during the study - You have previously failed both infliximab and ustekinumab Talk to your doctor to see if this trial is right for you.